Choose your region

Don't see your region/country
listed? Visit our global website

Press Releases

Date Title and Summary Additional Formats
Mar 13, 2008
- First hepatitis C protease inhibitor to begin Phase 3 clinical development - - Trial designed to confirm potential of telaprevir to increase sustained viral response (SVR) rates with 24-week treatment duration -
Feb 29, 2008
CAMBRIDGE, Mass., Feb 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the Company will participate in an HCV panel, entitled: "HCV: Protease Inhibitors and Beyond" at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in
Feb 19, 2008
CAMBRIDGE, Mass., Feb 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5
Feb 13, 2008
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes CAMBRIDGE, Mass., Feb 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Feb 12, 2008
CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.
Feb 11, 2008
CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
Feb 11, 2008
-- Focused on first-to-market opportunity with HCV protease
inhibitor telaprevir --

-- Additional drug candidates directed at HCV, cystic fibrosis and
immune-mediated diseases--
Feb 08, 2008
CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008 at 10:15 a.m. EST.
Jan 31, 2008
CAMBRIDGE, Mass., Jan 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5, 2008 at 11:40 a.m.
Jan 28, 2008
CAMBRIDGE, Mass., Jan 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2007 financial results on Monday, February 11, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
Jan 23, 2008
-- Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens -- Vertex plans concurrent second study to support registration -- Final data from both trials anticipated in mid- 2010
Jan 07, 2008
- Formal European scientific advice obtained for telaprevir development program - - Meeting scheduled with FDA for January 2008 on Phase 3 trial design and recent data - - Next-generation HCV protease inhibitor and two investigational compounds for cystic fibrosis in clinical development -
Jan 03, 2008
CAMBRIDGE, Mass., Jan 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008 at 2:00 p.m. PST (5:00 p.m. EST).
Nov 21, 2007
CAMBRIDGE, Mass., Nov 21, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference on Wednesday, November 28, 2007 at 8:45 a.m. EST.
Nov 20, 2007
-- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers -- -- Merck to initiate clinical development of VX-689 --
Nov 05, 2007
Cambridge, MA, November 5, 2007 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 2:45 p.m.
Nov 02, 2007
Two Large Phase 2 Trials of Telaprevir, an Investigational Hepatitis C Protease Inhibitor, Dosed in Combination with Pegylated Interferon and Ribavirin Show SVR Rates of 61% and 65% Initial Rapid Viral Decline Appears Important to Achieve SVR Safety Profile Consistent with Prior Interim Analyses
Oct 29, 2007
Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD – Additional compounds for HCV and Cystic Fibrosis scheduled to enter development – Cambridge, MA, October 29, 2007 — Vertex
Oct 09, 2007
CAMBRIDGE, Mass., Oct 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2007 financial results on Monday, October 29, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
Sep 28, 2007
-- Conference Presentations to Include Data from Two Randomized, Controlled Phase 2 Clinical Studies of Investigational HCV Protease Inhibitor Telaprevir --